李杰                                                    

學(xué)歷：理學(xué)博士

專家類別：助理研究員,，碩導(dǎo)

郵箱：[email protected]

通訊地址：云南省昆明市呈貢區(qū)雨花街道春融西路1168號

郵編：650500

課題組網(wǎng)站：http://biotrainee.vip:25164/LeeLab_demo/index.html

簡歷

2011.09 -2016.06,哈爾濱醫(yī)科大學(xué),，生物信息科學(xué)與技術(shù)學(xué)院,，學(xué)士

2016.09 -2019.06,哈爾濱醫(yī)科大學(xué)，生物信息科學(xué)與技術(shù)學(xué)院,，碩士

2019.09 - 2023.07,清華大學(xué),，醫(yī)學(xué)院，博士

2023.08–至今,，昆明醫(yī)科大學(xué),生物醫(yī)學(xué)工程研究院,助理研究員

研究方向

近年來借助生物信息學(xué)與分子生物學(xué)的研究方法，深入研究了與人類復(fù)雜疾病相關(guān)的biomarker識別,、cfDNA液體活檢的臨床應(yīng)用,、及基因多組學(xué)的分子機(jī)制。成功識別了腫瘤病人與健康個體之間的生物標(biāo)志物差異,，以及不同腫瘤組織來源的差異性,。通過機(jī)器學(xué)習(xí)技術(shù)，構(gòu)建了識別腫瘤病人及區(qū)分腫瘤來源的模型,，進(jìn)而實現(xiàn)了泛癌的無創(chuàng)早篩,，為廣大腫瘤患者帶來福音。還為臨床監(jiān)控癌癥復(fù)發(fā),、評估藥物耐受性提供了新思路,。如此，液體活檢得以快速,、方便地在臨床實踐中應(yīng)用,，為個體化精準(zhǔn)醫(yī)療系統(tǒng)的研發(fā)提供了堅實的理論、算法及實驗基礎(chǔ),。

承擔(dān)科研項目

1. 國家自然科學(xué)基金委員會,青年科學(xué)基金項目,，82404091，基于cfDNA動態(tài)靶向識別乳腺癌復(fù)發(fā)風(fēng)險及分子亞型的技術(shù)和應(yīng)用研究,，2025-01至2027-12,，直接經(jīng)費30萬元；主持,；

2. 國家自然科學(xué)基金委員會,，專項項目，82141102,，胰島素瘤激素異常合成機(jī)制研究,，2022-01至2024-12，直接經(jīng)費250萬元,；參與,；

研究成果（論文、專利、專著等）

主要工作

1. Xu C#, Xia P#, Li J#, Lewis KB, Ciombor KK, Wang L, Smith JJ, Beauchamp RD, Chen XS. Discovery and validation of a 10-gene predictive signature for response to adjuvant chemotherapy in stage II and III colon cancer. Cell Rep Med. 2024 Aug 20;5(8):101661. doi: 10.1016/j.xcrm.2024.101661. Epub 2024 Jul 25. PMID: 39059386.(IF=16.9)

2.Chen Y, Zheng Q, Wang H, Tang P, Deng L, Li P, Li H, Hou J,Li J*, Wang L*, Peng J*. Integrating transcriptomics and proteomics to analyze the immune microenvironment of cytomegalovirus associated ulcerative colitis and identify relevant biomarkers. BioData Min. 2024 Aug 27;17(1):26. doi: 10.1186/s13040-024-00382-0. PMID: 39192288; PMCID: PMC11348729.(IF=4.5)

3.Li J#, Chen J#, Sun X#, Yang H#, Sun K, Liu C, Wang Y, Xu M, Ji X, Zhang J, Wu X, Wang A, Fan B, Zhang X, Wu Y, Cui P, Peng J, Zhao Y, Wu W, Yu H, Bu Z, Ji J, Lan X. Uncovering chromatin accessibility and cancer diagnostic potential via cell-free DNA utilization. Sci Bull (Beijing). 2024 Apr 8:S2095-9273(24)00247-0. doi: 10.1016/j.scib.2024.04.013. Epub ahead of print. PMID: 38664094.(IF=20.6)

4.Xiaolu Zhang, Jingwei Li, Xun Lan, Jie Li. Cell‐free DNA‐associated multi‐feature applications in cancer diagnosis and treatment. Clin. Transl. Disc. 2024;4:e280. doi: 10.1002/ctd2.280.(IF=暫無)

5.Li J#, Sun X, Yang H, Chen J, Bu Z, Ji J, Lan X*;Integrated analysis toolkit for dissecting whole-genome-wide features of cell-free DNA.Clin Transl Med,；2023 Mar;13(3):e1212. doi: 10.1002/ctm2.1212,；(IF=11.492)

6.Huanhuan Pang#, Yisheng Jiang#, Jie Li#, Yushen Wang#, Meng Nie#, Nan Xiao, Shuo Wang, Zhihong Song, Fansen Ji,Yafei Chang, Yu Zheng, Ke Yao, LiAng Yao, Shao Li, Peng Li, Lei Song, Xun Lan, Zhiheng Xu, Zeping Hu. Pang H, Jiang Y, Li J, Wang Y, Nie M, Xiao N, Wang S, Song Z, Ji F, Chang Y, Zheng Y, Yao K, Yao L, Li S, Li P, Song L*, Lan X*, Xu Z*, Hu Z*. Aberrant NAD+ metabolism underlies Zika virus-induced microcephal；Nature Metabolism,；2021 Aug;3(8):1109-1124. doi: 10.1038/s42255-021-00437-0. Epub 2021 Aug 12,；(IF=20.8)

7. Chen J#, Sun Y#,Li J#, Lyu M#, Yuan L#, Sun J, Chen S, Hu C, Wei Q, Xu Z, Guo T, Cheng X. In-depth metaproteomics analysis of tongue coating for gastric cancer: a multicenter diagnostic research study.Microbiome. 2024 Jan 8;12(1):6. doi: 10.1186/s40168-023-01730-8. PMID: 38191439; PMCID: PMC10773145. (IF=16.837)

8.J Li#, W Wang#, P Xia#, L Wan#, L Zhang, L Yu, L Wang, X Chen*, Y Xiao*, C Xu*。Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in patients with breast cancer,；International journal of cancer,；2018 Nov 1;143(9):2150-2160. doi: 10.1002/ijc.31573；(IF=7.396)

9.Jie Li, Xun Lan *. Perspective on new cell-free DNA technologies for early cancer detection,；Cancer Biology & Medicine,；2023 Aug 8:j.issn.2095-3941.2023.0159. doi: 10.20892/j.issn.2095-394；(IF=5.5)

10. J Li#, M Xu#, J Peng#, J Wang, Y Zhao, W Wu, X Lan*.Novel technologies in cfDNA analysis and potential utility in clinic,；Chinese Journal of Cancer Research,；2021 Dec 31;33(6):708-718. doi: 10.21147/j.issn.1000-9604.2021.06.07； (IF=5.894)

11. 發(fā)明人：藍(lán)勛,；季加孚,；步召德；李杰,；陳佳輝,；孫克用；孫欣,。一種基于cfDNA組學(xué)特性的癌癥無創(chuàng)早篩方法（國家發(fā)明專利）,。中國; ZL202110118814.5; 2022年7月19日。

其他工作

1. C Xu, R Qi, Y Ping, J Li, H Zhao, L Wang, MY Du, Y Xiao, X Li. Systemically identifying and prioritizing risk lncRNAs through integration of pan-cancer phenotype associations.Oncotarget. 8 (7), 12041.

2. 2. Chaohan Xu, Yanyan Ping, Hongying Zhao, Shangwei Ning, Peng Xia, Weida Wang, Linyun Wan,Jie Li, Li Zhang, Lei Yu, Yun Xiao. LncNetP, a systematical lncRNA prioritization approach based on ceRNA and disease phenotype association assumptions.Oncotarget. 8 (70), 114603.

3. 3. Shuyuan Wang, Peng Xia, Li Zhang, Lei Yu, Hui Liu, Qianqian Meng, Siyao Liu, Jie Li, Qian Song, Jie Wu, Weida Wang, Lei Yang, Yun Xiao, Chaohan Xu. Systematical identification of breast cancer related circular RNA modules for deciphering circRNA functions based on the non-negative matrix factorization algorithm.International journal of molecular sciences. 20 (4), 919.

4. Xianze Wang, Hao Chen, Rui Jiang, Xiafei Hong, Junya Peng, Wenyan Chen, Jialin Jiang,Jie Li, Dan Huang, Hongmei Dai, Wenze Wang, Junliang Lu, Yupei Zhao, Wenming Wu. Interleukin-17 Aactivates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma.Cancer Letters. 508, 1-12.

擔(dān)任過Science Bulletin,Briefs in Bioinformatics, Frontiers in oncology, International journal of cancer審稿人,。